Updates

** Shares of drugmaker AbbVie ABBV.N fall 5.1% to $208.53 in afternoon trade

** Brokerage BNP Paribas maintains AbbVie at "neutral", sets price target at $213

** Brokerage says J&J's JNJ.N FDA approval of once-daily oral psoriasis drug Icotyde could compete with AbbVie's Skyrizi, a key growth driver

** Brokerage adds Skyrizi should remain well-positioned due to strong efficacy and 12-week dosing after induction, supporting patient compliance

** Brokerage says an oral option could expand the psoriasis market beyond current 30%–40% penetration, leaving room for Skyrizi growth

** Forecasts Skyrizi to grow 23% in FY26, representing a key growth driver for AbbVie, brokerage says

** J&J is also testing Icotyde in arthritis and bowel diseases, which could ramp up future competition, BNP said

** ABBV shares down 8.4% in 2025

(Reporting by Sahil Pandey and Siddhi Mahatole in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))